Subsequent systemic therapy for non-small cell lung cancer patients with immune checkpoint inhibitor-related interstitial lung disease.
Sato Y, Watanabe S, Ota T, Kushiro K, Fujisaki T, Takahashi M, Ohtsubo A, Shoji S, Nozaki K, Ichikawa K, Hokari S, Kondo R, Hayashi M, Ishikawa H, Miyabayashi T, Abe T, Miura S, Tanaka H, Okajima M, Terada M, Ishida T, Iwashima A, Sato K, Yoshizawa H, Aoki N, Ohshima Y, Koya T, Kikuchi T.
Sato Y, et al. Among authors: hokari s.
Transl Lung Cancer Res. 2021 Jul;10(7):3132-3143. doi: 10.21037/tlcr-21-198.
Transl Lung Cancer Res. 2021.
PMID: 34430353
Free PMC article.